<DOC>
	<DOCNO>NCT01672086</DOCNO>
	<brief_summary>The active surveillance post-approval study Stelkast Surpass Acetabular System retrospective , multi-center , single-arm study intend collect data survivorship long-term safety effectiveness device .</brief_summary>
	<brief_title>Active Surveillance Post-Approval Atudy Stelkast Surpass Acetabular System</brief_title>
	<detailed_description>This active surveillance study intend evaluate survivorship long-term safety effectiveness Stelkast Surpass Acetabular System . Neither patient surgeon blind treatment . The study compare Surpass ' survivorship survivorship observe historical control group establish meta-analysis . The evaluation conduct period ten year . These evaluation record onsite visit and/or mailing send physician request deidentified patient-level data subject implant Surpass system .</detailed_description>
	<mesh_term>Calcium Carbonate</mesh_term>
	<criteria>Primary hip arthroplasty Skeletal maturity Noninflammatory degenerative joint disease osteoarthritis , avascular necrosis , congenital hip dysplasia , traumatic arthritis The Stelkast Surpass Acetabular System contraindicate patient follow condition : Overt latent infection around hip joint , insufficient bone stock allow appropriate insertion fixation prosthesis , insufficient soft tissue integrity provide adequate stability , muscle laxity inadequate soft tissue proper function healing , mental neuromuscular disorder allow control affect joint , revision hip arthroplasty , inflammatory hip joint disease , neuropathic hip joint disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>